



US009409931B1

(12) **United States Patent**
Baran et al.

(10) **Patent No.:** **US 9,409,931 B1**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **3-O-ACYL-INGENOL ANALOGUES**

(71) Applicant: **LEO LABORATORIES LIMITED**,
Dublin (IE)

(72) Inventors: **Phillippe S. Baran**, La Jolla, CA (US);
Jakob Felding, Ballerup (DK); **Yehua Jin**,
La Jolla, CA (US); **Chien-Hung Yeh**,
La Jolla, CA (US)

(73) Assignee: **LEO LABORATORIES LIMITED**,
Dublin (IE)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/739,731**

(22) Filed: **Jun. 15, 2015**

(51) **Int. Cl.**
C07C 69/75 (2006.01)
A61K 31/215 (2006.01)
A61K 31/695 (2006.01)
C07F 7/08 (2006.01)

(52) **U.S. Cl.**
CPC **C07F 7/0834** (2013.01); **A61K 31/215**
(2013.01); **A61K 31/695** (2013.01); **C07C**
69/75 (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO WO 2012/083954 A1 6/2012

OTHER PUBLICATIONS

Liang et al. *Bioorganic & Medicinal Chemistry Letters*, 2013, 23,
5624-5629.*

Challacombe et al., "Neutrophils Are a Key Component of the Anti-
tumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate",
The Journal of Immunology, vol. 177, 2006, pp. 8123-8132.

Cozzi et al., "Induction of Senescence in Diterpene Ester-Treated
Melanoma Cells via Protein Kinase C-Dependent Hyperactivation of
the Mitogen-Activated Protein Kinase Pathway", *Cancer Research*,
vol. 66, No. 20, Oct. 15, 2006, pp. 10083-10091.

Ersvaer et al., "The Protein Kinase C Agonist PEP005 (Ingenol
3-Angelate) in the Treatment of Human Cancer: A Balance between
Efficacy and Toxicity", *Toxins*, vol. 2, Jan. 22, 2010, pp. 174-194.

Evans et al., "A New Ingenol Type Diterpene From the Irritant Fractions
of *Euphorbia Myrsinites* and *Euphorbia Biglandulosa*"
Phytochemistry, vol. 13, 1974, pp. 2324-2325.

Hampson et al., "PEP005, a selective small-molecule activator of
protein kinase C, has potent antileukemic activity mediated via the
delta isoform of PKC", *Blood*, vol. 106, No. 4, Aug. 15, 2005
(Prepublished online Apr. 21, 2005), pp. 1362-1368.

Hampson et al., "The anti-tumor agent, ingenol-3-angelate
(PEP005), promotes the recruitment of cytotoxic neutrophils by activation
of vascular endothelial cells in a PKC- σ dependent manner",
Cancer Immunol Immunother., vol. 57, 2008 (Published online Feb.
12, 2008), pp. 1241-1251.

Jørgensen et al., "14-Step Synthesis of (+)-Ingenol from (+)-3-
Carene", *Scienceexpress*, Aug. 1, 2013, pp. 1-7.

Le et al., "Immunostimulatory cancer chemotherapy using local
ingenol-3-angelate and synergy with immunotherapies", *Vaccine*,
vol. 27, 2009 (Available online Apr. 3, 2009), pp. 3053-3062.

Marco et al., "Ingenane and Lathyrane Diterpenes from the Latex of
Euphorbia Canariensis", *Phytochemistry*, vol. 45, No. 3, 1997, pp.
563-570.

Ogbourne et al., "Antitumor Activity of 3-Ingenyl Angelate: Plasma
Membrane and Mitochondrial Disruption and Necrotic Cell Death",
Cancer Research, vol. 64, Apr. 15, 2004, pp. 2833-2839.

Paquette et al., "Regioselective Routes to Nucleophilic Optically
Active 2- and 3-Carene Systems", *J. Org. Chem.*, vol. 55, No. 5, 1990,
pp. 1589-1598.

Rosen et al., "Dual mechanism of action of ingenol mebutate gel for
topical treatment of actinic keratoses: Rapid lesion necrosis followed
by lesion-specific immune response", *J. Am Acad. Dermatol.*, vol.
66, No. 3, Mar. 2012, pp. 486-493.

Upadhyay et al., "Presence of Ingenol and a New Diterpene 4-Deoxy
Ingenol in the Latex of *Euphorbia Megalantha* (BOISS)", *Current
Science*, vol. 56, No. 20, Oct. 20, 1987, pp. 1058-1059.


* cited by examiner

Primary Examiner — Yevegeny Valenrod

(74) *Attorney, Agent, or Firm* — Birch, Stewart, Kolasch &
Birch, LLP

(57) **ABSTRACT**

The present invention relates to a compound according to
formula I



wherein R₁ represents hydrogen, R₂ represents hydroxyl and
R₃ represents hydroxyl;

or R₁ represents hydroxyl and R₂ represents hydroxyl and R₃ represents
hydrogen;

or R₁ represents methyl, R₂ represents hydrogen and R₃ represents
hydroxyl;

or R₁ represents methyl, R₂ represents hydrogen and R₃ represents
hydrogen;

or pharmaceutically acceptable hydrates or solvates thereof.

The invention further relates to said compounds for use as
a medicament, to pharmaceutical compositions comprising
said compounds, to methods of treating diseases with
said compounds and to intermediates for the preparation of
said compounds.

13 Claims, No Drawings